CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Orgenesis Inc   (ORGS)
Other Ticker:  
 

Orgenesis Inc 's Leverage Ratio

ORGS's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to repayements of liabilities of -52.38% Orgenesis Inc improved Leverage Ratio in second quarter 2023 to 1.28, below the company's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the second quarter 2023, 376 other companies have achieved lower Leverage Ratio than Orgenesis Inc in the II Quarter 2023. While Leverage Ratio total ranking has improved so far in the second quarter 2023 to 2506, from total ranking in the first quarter 2023 at 3316 .

Explain Leverage Ratio?
Who are ORGS Customers?
What are ORGS´s Total Liabilities?


ORGS Leverage Ratio (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Equity Change -24.74 % -16.79 % -24.75 % -30.08 % -38.17 %
Y / Y Total Liabilities Change -0.2 % 175.35 % 198.09 % 89.36 % 31.32 %
Leverage Ratio MRQ 1.28 2.22 2.13 1.34 0.96
ORGS's Total Ranking # 2506 # 3316 # 3513 # 2953 # 2421
Seq. Equity Change -17.37 % -0.23 % -3.9 % -5 % -8.65 %
Seq. Total Liabilities Change -52.38 % 3.89 % 52.82 % 32 % 31.39 %

New: More ORGS's historic Leverage Ratio results >>


Leverage Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 377
Healthcare Sector # 746
Overall Market # 2498


Leverage Ratio Statistics
High Average Low
9.22 1.67 0.28
(Dec 31 2019)   (Sep 30 2020)




Financial Statements
Orgenesis Inc 's Equity $ 24 Millions Visit ORGS's Balance sheet
Orgenesis Inc 's Total Liabilities $ 31 Millions Visit ORGS's Balance sheet
Source of ORGS's Sales Visit ORGS's Sales by Geography


Cumulative Orgenesis Inc 's Leverage Ratio

ORGS's Leverage Ratio for the trailling 12 Months

ORGS Leverage Ratio

 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Equity TTM Growth -24.74 % -16.79 % -24.75 % -30.08 % -38.17 %
Y / Y Total Liabilities TTM Growth -0.2 % 175.35 % 198.09 % 89.36 % 31.32 %
Leverage Ratio TTM 1.76 1.64 1.24 0.85 0.65
Total Ranking TTM # 103 # 10 # 8 # 1420 # 6
Seq. Equity TTM Growth -17.37 % -0.23 % -3.9 % -5 % -8.65 %
Seq. Total Liabilities TTM Growth -52.38 % 3.89 % 52.82 % 32 % 31.39 %

Leverage ratio ranking by company, industry and sector >> Back to ORGS Financial Strength Comparisons >> Compare ORGS Leverage Ratio to its Peers

On the trailing twelve months basis Despite of the repayements of liabilities of -52.38% in the trailing twelve months ending in II Quarter 2023, Leverage Ratio improved to 1.76, above Orgenesis Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 7, during the past 12 months, other companies have achieved lower Leverage Ratio than Orgenesis Inc . While Leverage Ratio total ranking has deteriorated during the twelve months ending in the II Quarter 2023, compared to the prior period, from 10 to 103.

Explain Leverage Ratio?
Who are ORGS Customers?
What are ORGS´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 8
Healthcare Sector # 26
Within the Market # 103


trailing twelve months Leverage Ratio Statistics
High Average Low
0.69 0.29 0.1
(Dec 31 2019)   (May 31 2017)




Companies with similar Leverage Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Leverage RatioJun 30 2023 MRQ Total LiabilitiesJun 30 2023 MRQ Equity
Qualigen Therapeutics Inc   3.36 $ 11.115  Millions$ 3.308  Millions
Iterum Therapeutics Plc  3.32 $ 23.641  Millions$ 7.129  Millions
Sarepta Therapeutics Inc   3.16 $ 2,339.490  Millions$ 741.411  Millions
Panbela Therapeutics Inc  3.07 $ 14.749  Millions$ 4.802  Millions
Rockwell Medical inc   2.99 $ 28.509  Millions$ 9.528  Millions
Arcutis Biotherapeutics Inc   2.98 $ 240.181  Millions$ 80.508  Millions
Trevena Inc  2.97 $ 29.077  Millions$ 9.782  Millions
Tempest Therapeutics Inc   2.93 $ 14.708  Millions$ 5.012  Millions
Sellas Life Sciences Group Inc   2.83 $ 13.723  Millions$ 4.843  Millions
Kala Bio inc   2.80 $ 49.008  Millions$ 17.492  Millions
Innovation Pharmaceuticals Inc   2.69 $ 5.478  Millions$ 2.039  Millions
China Pharma Holdings Inc   2.61 $ 11.352  Millions$ 4.353  Millions
Blueprint Medicines Corporation  2.56 $ 795.315  Millions$ 311.130  Millions
Addex Therapeutics Ltd  2.53 $ 2.893  Millions$ 1.145  Millions
Marinus Pharmaceuticals Inc   2.48 $ 142.305  Millions$ 57.339  Millions
Aytu Biopharma Inc   2.47 $ 97.106  Millions$ 39.357  Millions
Mersana Therapeutics Inc   2.46 $ 221.200  Millions$ 89.800  Millions
Reviva Pharmaceuticals Holdings Inc   2.40 $ 3.883  Millions$ 1.621  Millions
Proqr Therapeutics N v   2.33 $ 108.072  Millions$ 46.357  Millions
Reata Pharmaceuticals Inc   2.27 $ 198.223  Millions$ 87.291  Millions
Cyclacel Pharmaceuticals Inc   2.20 $ 11.306  Millions$ 5.136  Millions
Mira Pharmaceuticals Inc   2.20 $ 2.629  Millions$ 1.197  Millions
Phibro Animal Health Corporation  2.16 $ 609.036  Millions$ 282.509  Millions
Clene Inc   2.15 $ 46.312  Millions$ 21.533  Millions
Casi Pharmaceuticals inc   2.11 $ 51.103  Millions$ 24.165  Millions
Innovation1 Biotech Inc   2.08 $ 2.605  Millions$ 1.252  Millions
Zoetis Inc   1.97 $ 9,124.000  Millions$ 4,621.000  Millions
Maravai Lifesciences Holdings Inc   1.94 $ 1,743.866  Millions$ 897.638  Millions
Sonnet Biotherapeutics Holdings Inc   1.94 $ 6.616  Millions$ 3.418  Millions
Bristol myers Squibb Company  1.92 $ 61,516.000  Millions$ 32,030.000  Millions

Date modified: 2023-08-21T10:45:04+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com